the aid library

Filter

309

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (28 October 2021), updated 15 March 2022

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. Th ... more

Geographical, landscape and host associations of Trypanosoma cruzi DTUs and lineages

Izeta-Alberdi, A.; Ibarra-Cerdena, C.; Moo-llanes, D.; Ramsey,J. BMC Part of Springer Nature (2016) CC

Trypanosoma cruzi is the etiological agent of Chagas disease (CD), considered one of the most important parasitic infections in Latin America. Between 25 and 90 million humans are at infection risk via at least one of multiple infection mechanisms. Under natural conditions, the principal transmissio ... more

Implementation of simultaneous diagnostic testing for COVID-19 and TB in high TB burden countries

Stop TB Partnership; WHO (2022) C_WHO

Tuberculosis (TB) is the deadliest infectious disease in most low- and middle-income countries, claiming more than 4,000 lives each day. The unprecedented COVID-19 pandemic has seriously impacted people with pre-existing health conditions. People with TB are usually more vulnerable to other infectio ... more

Schistosomiasis diagnosis: Challenges and opportunities for elimination

Ally O, Kanoi BN, Ochola L, (2024) CC

PLoS Negl Trop Dis 18(7): e0012282. This review highlights common diagnostic approaches for detecting schistosomiasis in field and clinical settings, major challenges, and provides new and novel opportunities and diagnosis pathways that will be critical in sup- porting elimination of schistosomi ... more

International Standards For Tuberculosis Care

Tuberculosis Coalition for Technical Assistance (TBCTA), USAID (2014) C2

3rd edition

National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults

Federal Ministry of Health Nigeria , World Health Organisation (WHO) (2010) C_WHO

ТБ/ВИЧ Клиническое Руководство

нтон Харрис, Дермот Махер, Стивен Грэхем et al. World Health Organization (2006) C_WHO

Клиническое Руководство

Eliminación de la TB - Vacuna BCG

Centers for Disease Control and Prevention (2012) C_CDC

Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes

World Health Organization World Health Organization WHO (2021) C_WHO

Health ministries currently lack effective tools for monitoring and evaluation of schistosomiasis control programmes. Egg detection can be used, but the cost, challenges of obtaining samples, and the need for trained personnel and equipment limit the frequency of monitoring. The purpose of this TPP ... more

Definição e categorização do momento da transmissão vertical do SARS-CoV-2 Informe científico 8 de fevereiro de 2021

Organização Mundial da Saúde (OMS) OPAS, OMS (2021) C_WHO

Definition and categorization of the time of vertical transmission of SARS-CoV-2 Scientific report 8 February 2021

The Global Burden of Disease Study at 30 years

Murray, C.J.L. nature medicine (2022) CC

The Global Burden of Disease Study (GBD) began 30 years ago with the goal of providing timely, valid and relevant assessments of critical health outcomes. Over this period, the GBD has become progressively more granular. The latest iteration provides assessments of thousands of outcomes for diseases ... more

Update on oral Chagas disease outbreaks in Venezuela: epidemiological, clinical and diagnostic approaches

Alcáron de Noya, B.; Z. Diaz-Bello, C. Colmenares, et al. (2015) CC

Mem Inst Oswaldo Cruz , Rio de Janeiro, Vol. 110 (3): 377-386, May 2015

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment

Fuss, A.; H. D. Mazigo and A. Mueller (2020) CC

Infectious Diseases of Poverty (2020) 9:74 To detect acute schistosomiasis, low-intensity infections, or to verify the success of treatment with praziquantel, highly sensitive test methods are required. The aim of this study was therefore to demonstrate the performance of Schistosoma mansoni spec ... more

Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer

World Health Organization WHO (2020) C_WHO

This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the ... more

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India + Annexures

Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare (2012) C1